ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Summary

This phase Ib trial studies the side effects and best dose of ALRN-6924 when given together with paclitaxel in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ALRN-6924 and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start

2019-01-24

Primary completion

2026-03-11

Completion

2026-03-11

Publications

• Berglund H, Salomonsson SL, Mohajershojai T, Gago FJF, Lane DP, Nestor M. p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):768-778. doi: 10.1007/s00259-023-06462-3. Epub 2023 Oct 12.

Drugs

Indications